Shot:    

• The P-III ORIENT-32 involves assessing of Tyvyt (sintilimab) + Byvasda (bevacizumab- biosimilar) vs sorafenib in a ratio (2:1) for 1L treatment of patients with advanced HCC
• The study resulted in meeting its 1EPs of PFS and OS- the safety profile is consistent with prior studies- and no new safety signals were identified. Following the IDMC recommendation- Innovent to review the results with NMPA’s CDE in China
• Tyvyt is a type of IgG4 mAb- that binds to PD-1 molecules on the surface of T-cells- blocking the PD-1 pathway and reactivates T-cells to kill cancer cells. The company is evaluating Tyvyt in 20+ studies across multiple cancer indications globally

­ Ref: Innovent | Image: Innovent